Preventing HIV/STI in Urban Adolescents Via an mHealth Primary Care Intervention

Sponsor
University of Michigan (Other)
Overall Status
Completed
CT.gov ID
NCT03368456
Collaborator
(none)
100
1
2
27.4
3.6

Study Details

Study Description

Brief Summary

The study evaluates the preliminary efficacy of an innovative mobile-health (mHealth) intervention (hereon referred to as S4E) to improve human immunodeficiency virus and sexually transmitted infection testing and reduce HIV/STI risk behaviors in a clinic sample (n=100) of at-risk youth ages 14-21 living in Southeast Michigan. A Stage I randomized control trial will be conducted to examine the preliminary efficacy of S4E, relative to Usual Care (UC), over a period of six months.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: S4E
  • Behavioral: Usual Care
N/A

Detailed Description

HIV/STI and drug abuse remain significant public health priorities in the US and youth are disproportionately affected. Youth between the ages of 15 - 24 constitute 25% of the sexually experienced population, yet account for 46% and 50% of HIV infections and new STIs, respectively. National surveillance data indicate that youth disproportionately engage in HIV/STI risk behaviors, including condomless sex and licit and illicit drug use, which increase their risk for HIV/STI infection. Despite the disproportionately high rates of HIV/STI infection and risk behaviors in youth, fewer than 14% report having ever been tested for HIV and many are not routinely screened for asymptomatic STIs as recommended by the Center for Disease Control. In Southeast Michigan, HIV/STI are disproportionately high. To address these significant public health concerns, a mobile-health (mHealth) intervention was developed for health clinic settings. The proposed research aims to develop a cross-platform and universal version of S4E. The cross-platform and universal version of S4E will be compatible with both IOS and Android operating systems, and multiple mobile devices, aimed at providing adolescents with ongoing access to the intervention once they leave the clinic. The proposed research will also evaluate the preliminary efficacy of S4E to improve HIV/STI testing and reduce HIV/STI risk behaviors in a clinic sample (n=100) of at-risk youth ages 14-21 living in Southeast Michigan by conducting a Stage I RCT to examine the preliminary efficacy of S4E, relative to Usual Care, among a sample of 100 at-risk youth over six months.

Study Design

Study Type:
Interventional
Actual Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
To test the preliminary efficacy of S4E, we will conduct a Stage I RCT and use a mixed between/within-subjects design with two levels of intervention (S4E and Usual Care) as the between-subjects factor and three repeated measures assessments (Baseline, 3-, and 6-months post-Baseline) as the within-subjects factor.To test the preliminary efficacy of S4E, we will conduct a Stage I RCT and use a mixed between/within-subjects design with two levels of intervention (S4E and Usual Care) as the between-subjects factor and three repeated measures assessments (Baseline, 3-, and 6-months post-Baseline) as the within-subjects factor.
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Preventing HIV/STI in Urban Adolescents Via an mHealth Primary Care Intervention
Actual Study Start Date :
May 1, 2018
Actual Primary Completion Date :
Aug 12, 2020
Actual Study Completion Date :
Aug 12, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: S4E App Intervention

Participants in the S4E condition will first receive the intervention in the waiting area via iPads provided for them. Content includes the theoretically driven components of Storytelling for Empowerment: (a) Storytelling scenarios, (b) drug use and HIV/STI knowledge development, (c) interactive activities, (d) increasing self-efficacy to prevent/reduce sexual risk and drug use behaviors, and increase HIV/STI testing, (e) clinician-youth communication, and (f) highlighting prevention principles

Behavioral: S4E
S4E application was developed in collaboration with youth in Southeast Michigan. S4E aims to prevent and reduce HIV/STI risk behaviors, including drug use and sexual risk behaviors, and increase HIV/STI testing among youth. Content produced for the application is based on scientific prevention principles in conjunction with youth input. To date, we have developed modules focused on youth alcohol & drug use, HIV & STIs and a forthcoming module on tobacco prevention and cessation.

Placebo Comparator: Usual Care Condition

Participants in Usual Care (i.e., Control Condition) will not receive the S4E intervention. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources, and reproductive and healthcare services.

Behavioral: Usual Care
Participants in Usual Care (i.e., Control Condition) will not receive the S4E intervention from the study staff. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources, and reproductive and healthcare services.

Outcome Measures

Primary Outcome Measures

  1. Change in Adolescent HIV Testing [baseline, 3 and 6 month post-baseline]

    Post-intervention, we will assess whether youths requested to receive HIV testing at the clinic, and at 3 and 6 months post-baseline (yes/no).

Secondary Outcome Measures

  1. Change in condomless sex behaviors [3 and 6 month post-baseline]

    Adolescent unsafe sexual behavior will be measured (time points 1-3) using items extracted from Jemmott, Jemmott, and Fong's Sexual Behavior instrument. This gated instrument will assess the adolescent's past 90-day condom use, number of sexual partners, and contraceptive use (non-condom).

  2. Change in drug use behaviors [baseline, 3 and 6 month post-baseline]

    Licit and illicit drug use behaviors will be assessed (time points 1-3) using items from the Monitoring the Future Study. Youth will be asked whether or not they have used licit or illicit drugs in their lifetime and the past 90 days. Youth who report "Yes" to past 90-day sex will be asked to report the frequency of drug use before sex. These measures have been used in our formative research.

Other Outcome Measures

  1. Change in Clinician-Youth Communication [baseline, 3 and 6 month post-baseline]

    Completed by both the clinician (α =.70) and youth (α =.69), clinician-youth communication will be assessed (time points 1-3) using items adapted from the Matched Pair Instrument (19 items; MPI). MPI assesses process and content of communication, including verbal and action-related behaviors performed by clinicians. Responses range from "1=strongly disagree," to "5=strongly agree," on a five-point Likert scale. A sample statement for clinicians and youths is, "Encouraged the patient/me to express his or her/my thoughts concerning drug use behaviors."

  2. Youth Self-Efficacy [baseline, 3 and 6 month post-baseline]

    Youth's self-efficacy will be assessed (time points 1-3) using two scales, including the Condom Self-Efficacy Scale (19 items, α =.85), and Drug Use Resistance Self-Efficacy (24 items, α =.98). Responses range from "1=not sure at all," to "4=definitely sure," on a four-point Likert scale. A sample question for the youth is, "How sure are you that you can refuse if a friend offers you marijuana at a party and you do not want it?"

Eligibility Criteria

Criteria

Ages Eligible for Study:
14 Years to 21 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Female or male youth 14-21 years of age

  • Sexually active

  • Live in Southeast Michigan

  • Have access to a smartphone or tablet

  • Youth must see an enrolled clinician to participate in the study.

Exclusion Criteria:
  • Report of prior psychiatric hospitalization by adolescent

  • Visible cognitive impairment due to drug use

  • Adolescent reports (tentative or firm) plans to move out of the Southeast Michigan area during the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Corner Health Center Ypsilanti Michigan United States 48198

Sponsors and Collaborators

  • University of Michigan

Investigators

  • Principal Investigator: David Cordova, PhD, University of Michigan

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
David Cordova, Assistant Professor, University of Michigan
ClinicalTrials.gov Identifier:
NCT03368456
Other Study ID Numbers:
  • HUM00158089
  • Previous HUM00118704
First Posted:
Dec 11, 2017
Last Update Posted:
Aug 21, 2020
Last Verified:
Aug 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by David Cordova, Assistant Professor, University of Michigan
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 21, 2020